Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
December 5, 2024 |
We are pleased to share that The Evidence Base have carried out a ‘deep dive’ into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights for real-world impact. The presentation had previously been delivered to a full house at ISPOR Europe 2024 by Priti Jhingran, Smita Kothari, Dominic Jones-Phillips, and Carole Longson, MBE.
In a dynamic healthcare landscape defined by evolving policies, shifting payer expectations, and changing pricing thresholds, stakeholder insights are essential to maintaining the relevance, adaptability, and effectiveness of economic models in addressing the needs of patients and healthcare systems. By integrating perspectives from clinicians, payers, providers, and patients into the development process, economic models are better positioned to withstand rigorous scrutiny in access and reimbursement evaluations, increasing their robustness and applicability in the real-world healthcare environment.
At ISPOR Europe 2024 (November 17–20, 2024, Barcelona, Spain), the presentation, “Planning with Insights: Even the Best Economic Models Need Validation,” delved into this topic, exploring a roadmap for building robust, stakeholder-informed economic models that effectively support reimbursement decisions while addressing the complexities of global markets. Using a case study to illustrate the impact of insights on economic models, the session, which drew a capacity crowd, was led by Priti Jhingran (Genesis Research Group) and included contributions from Dominic Jones-Phillips (Genesis Research Group), Smita Kothari (Merck & Co., Inc.) and Carole Longson, MBE (consultant).
“When you bake in insights in early stages of model development, you really have a higher likelihood of having a relevant model, as well as scientifically robust methodology used to develop the model. And what’s most important is that you get the framework right for the model.”
Also at ISPOR Europe 2024, Genesis Research Group led an issue panel on ‘Precision or Perception: Strategic Drug Pricing Anchored on Evidence’ with Priti Jhingran, PhD, Genesis Research Group, Christopher Blanchette, PhD, MBA, Novo Nordisk, Frank-Ulrich Fricke, PhD, Technische Hochschule Nürnberg, and Adam Weston, MSc, Genesis Research Group.
If you’d like copies of the slides for either presentation, please contact solutions@genesisrg.com.
Read more on ‘Planning with Insights: Even the Best Economic Models Need Validation’
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
We are pleased to share that The Evidence Base have carried out a 'deep dive' into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights...
Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...
Genesis Research Group unveils enhanced US market access data analytics
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...
Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers
Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.
Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program
Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...
Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’
ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...
How does Genesis Research Group ‘Innovate differently’?
New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...
Envision Analogue – An Introduction
Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...
World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group
A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...